Immobilized human PD-L1 at 0.5 μg/ml (50 μL/well) can bind to Durvalumab with a linear range of 1.221 ng/ml-5 μg/ml.
Product Details
Product Details
Product Specification
Host | Human |
Antigen | PD-L1 |
Synonyms | Programmed cell death 1 ligand 1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1, CD274, B7H1, PDCD1L1, PDCD1LG1 |
Accession | Q9NZQ7 |
Clone Number | S-SC0101 |
Antibody Type | Recombinant mAb |
Isotype | IgG1,k |
Application | Blocking of PD-1/PD-L1 signaling Functional assays |
Purification | Protein A |
Concentration | 2 mg/ml |
Endotoxin | <1EU/mg |
Conjugation | Unconjugated |
Physical Appearance | Liquid |
Storage Buffer | PBS pH7.4, containing no preservative |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
application | dilution | species |
ELISA | 1.221-5000 ng/ml |
Background
Durvalumab is an immunotherapy for cancer. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).
Picture
Picture
ELISA
